InMed Pharmaceuticals Inc.
Small molecule drug candidates targeting CB1/CB2 receptors and rare cannabinoid analogs
- Sector
- Biotech
- Headquarters
- VANCOUVER, A1
- Latest Form D
- $6M, Dec 2022
- Total capital
- $28.9M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $28.9M
- 5 Form D · last Dec 2022
- 47 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 5
- 5 pending · first 2024
- Rank in peer group#269 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 5th filing$6M
- Private capital raisedForm D · SEC · 4th filing$5M
- Private capital raisedForm D · SEC · 3rd filing$4.3M
- Private capital raisedForm D · SEC · 2nd filing$12M
- Private capital raisedForm D · SEC · 1st filing$1.6M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#269 · top 19%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Sazzad J. HossainResearcherExecutive OfficerLinked by 2 patents
- Adam A. CutlerDirectorNamed in SEC Form D filings
- Alexandra D.J. ManciniExecutive OfficerNamed in SEC Form D filings
- Andrew J. HullDirectorNamed in SEC Form D filings
- Bruce S. ColwillExecutive OfficerNamed in SEC Form D filings
- Bryan J. BaldasareDirectorNamed in SEC Form D filings
Show all 16 people
- Catherine A. SazdanoffDirectorNamed in SEC Form D filings
- Eric A. AdamsExecutive Officer, DirectorNamed in SEC Form D filings
- Eric C. HsuExecutive OfficerNamed in SEC Form D filings
- Janet J. GroveDirectorNamed in SEC Form D filings
- Jeff J. CharpentierExecutive OfficerNamed in SEC Form D filings
- Martin A. BottDirectorNamed in SEC Form D filings
- Michael D.J. WoudenbergExecutive OfficerNamed in SEC Form D filings
- Nicole J. LemerondDirectorNamed in SEC Form D filings
- Sarah A. LiExecutive OfficerNamed in SEC Form D filings
- William J. GarnerDirectorNamed in SEC Form D filings
What it has protected
USPTO · 5 granted of 10- PendingCannabinoid Analogs And Methods For Their PreparationUSPTOApplication 19368975
- GrantedCannabinoid Analogs And Methods For Their PreparationUSPTOUS 12,617,747
- GrantedTopical Formulations Of Cannabinoids And Use Thereof In The Treatment Of PainUSPTOUS 12,357,604
Show all 10 patent records
- Cannabinoid Analogs And Methods For Their PreparationJul 9, 2026 · Application 19368975Pending
- Cannabinoid Analogs And Methods For Their PreparationMay 5, 2026 · US 12,617,747Granted
- Topical Formulations Of Cannabinoids And Use Thereof In The Treatment Of PainJul 15, 2025 · US 12,357,604Granted
- Ocular Drug Delivery FormulationSep 10, 2024 · US 12,083,229Granted
- Metabolic Engineering Of E. Coli For The Biosynthesis Of Cannabinoid ProductsSep 3, 2024 · US 12,077,802Granted
- Use Of Topical Formulations Of Cannabinoids In The Treatment Of Epidermolysis Bullosa And Related Connective Tissue DisordersJul 23, 2024 · US 12,042,479Granted
- Compositions And Methods For Treating Neuronal Disorders With CannabinoidsNov 30, 2023 · Application 18033187Pending
- Compositions And Methods For Use Of Cannabinoids For NeuroprotectionFeb 9, 2023 · Application 17606003Pending
- Compositions And Methods For Biosynthesis Of Terpenoids Or Cannabinoids In A Heterologous SystemJun 2, 2022 · Application 17436548Pending
- Compositions And Methods For Use Of Cannabinol Compounds In NeuroprotectionApplication PCTUS2024028445Pending
Related companies, and why
- ADAPTIN BIO, INC.Similar federal contract value in Biotech · null in contracts
- Tolera Therapeutics IncSimilar federal contract value in Biotech · null in contracts
- IllExcor Therapeutics LLCSimilar federal contract value in Biotech · null in contracts
- Sunstone Therapies, Inc.Similar federal contract value in Biotech · null in contracts
- EvodiaBioSimilar federal contract value in Biotech · null in contracts
- MYCOBACTERIA THERAPEUTICS CORPORATIONSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .